Royalty Pharma buys royalty interest in Nuvalent cancer drugs for up to $315 mln [Seeking Alpha]
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
Royalty Pharma (NASDAQ:RPRX) was given a new $45.00 price target on by analysts at Leerink Partners.
Royalty Pharma (NASDAQ:RPRX) had its price target raised by analysts at TD Cowen from $42.00 to $45.00. They now have a "buy" rating on the stock.
Royalty Pharma (NASDAQ:RPRX) had its "buy" rating reaffirmed by analysts at Cowen Inc.